Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes

Lekakis, J; Vamvakou, G; Andreadou, I; Ganiatsos, G; Karatzis, E; Protogerou, A; Papaioannou, T; Ikonomidis, I; Papamichael, C; Mavrikakis, M

dc.contributor.author	Lekakis, J	en
dc.contributor.author	Vamvakou, G	en
dc.contributor.author	Andreadou, I	en
dc.contributor.author	Ganiatsos, G	en
dc.contributor.author	Karatzis, E	en
dc.contributor.author	Protogerou, A	en
dc.contributor.author	Papaioannou, T	en
dc.contributor.author	Ikonomidis, I	en
dc.contributor.author	Papamichael, C	en
dc.contributor.author	Mavrikakis, M	en
dc.date.accessioned	2014-03-01T01:54:55Z
dc.date.available	2014-03-01T01:54:55Z
dc.date.issued	2006	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27530
dc.subject	Acute Coronary Syndrome	en
dc.subject	Cardiovascular Disease	en
dc.subject	Coronary Disease	en
dc.subject	Cyclooxygenase	en
dc.subject	Endothelial Function	en
dc.subject	Oxidative Damage	en
dc.title	Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes	en
heal.type	journalArticle	en
heal.identifier.primary	10.1016/j.ijcard.2005.10.011	en
heal.identifier.secondary	http://dx.doi.org/10.1016/j.ijcard.2005.10.011	en
heal.publicationDate	2006	en
heal.abstract	BackgroundThe safe use of selective inhibitors of cyclooxygenase-2 in patients with cardiovascular disease has been questioned because of studies showing an increased risk of cardiac events. We examined the short-term effect of rofecoxib, a selective cyclooxygenase-2 inhibitor, on endothelial function, oxidative damage and inflammation in patients with acute coronary syndromes without ST-segment elevation.	en
heal.journalName	International Journal of Cardiology	en
dc.identifier.doi	10.1016/j.ijcard.2005.10.011	en